

Bibliographie Centre des Maladies du Sein

1. Zhang Y, Giacchetti S, Parouchev A, Hadadi E, Li X, Dallmann R, Xandri-Monje H, Portier L, Adam R, Lévi F, Dulong S, Chang Y: Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock. *Cell Cycle Georget Tex* 2018; 17:33–42
2. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, Minckwitz G von, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim S-B, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, et al.: Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2017; 18:1688–700
3. Debourdeau P, Espié M, Chevret S, Gligorov J, Elias A, Dupré PF, Desseaux K, Kalidi I, Villiers S, Giachetti S, Frere C, Farge D: Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study. *Cancer Med* 2017; 6:2732–44
4. Kim S-B, Dent R, Im S-A, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J, LOTUS investigators: Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol* 2017 doi:10.1016/S1470-2045(17)30450-3
5. Pivot X, Spano JP, Espié M, Cottu P, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Attar-Rabia H, Benkanoun C, Dima-Martinez L, Esposito N, Gligorov J: Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study. *Eur J Cancer Oxf Engl* 1990 2017; 82:230–6
6. Bousquet G, El Bouchtaoui M, Sophie T, Leboeuf C, Bazelaire C de, Ratajczak P, Giacchetti S, Roquancourt A de, Bertheau P, Verneuil L, Feugeas J-P, Espié M, Janin A: Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer. *Oncotarget* 2017; 8:35205–21
7. Giacchetti S, Hamy A-S, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu M-C, Bertheau P, Guinebretière JM, Saghatelian M, Lerebours F, Mazouni C, Tembo O, Espié M, Reyal F, Marty M, Asselain B, Pierga J-Y: Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. *Eur J Cancer Oxf Engl* 1990 2017; 75:323–32
8. Lemarignier C, Martineau A, Teixeira L, Vercellino L, Espié M, Merlet P, Groheux D: Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with (18)F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients. *Eur J Nucl Med Mol Imaging* 2017 doi:10.1007/s00259-017-3641-4
9. Groheux D, Martineau A, Teixeira L, Espié M, Cremoux P de, Bertheau P, Merlet P, Lemarignier C: (18)FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis. *Breast Cancer Res BCR* 2017; 19:3
10. Delaloge S, Bachelot T, Bidard F-C, Espié M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard A-C, Azria D, Jacquin J-P, Lemonnier J, Jacot W,

- Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, et al.: [Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]]. Bull Cancer (Paris) 2016 doi:10.1016/j.bulcan.2016.10.009
11. Luporsi E, Toledano A, Spaeth D, Scotté F, **Espié M**, Perot S, Duvillié L, Pithois Merli I, Bugat R: Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study). Support Care Cancer Off J Multinatl Assoc Support Care Cancer 2017; 25:973–82
12. Ruiz A, Wicherts DA, Sebagh M, **Giacchetti S**, Castro-Benitez C, Hillegersberg R van, Paule B, Castaing D, Morère J-F, Adam R: Predictive Profile-Nomogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results. Ann Surg Oncol 2017; 24:535–45
13. Soria JC, Bastian G, Bolotine L, Calais G, Ceraline J, de Cremoux P, **Espie M**, Karayan-Tapon L, Laprie A, Mazeron JJ, Negrier S, Roche H: [Academic carriers in oncology and radiotherapy: Explanations for the readers of Bulletin du Cancer]. Bull Cancer 2016; 103: 719-29
14. Quero L, Guillerm S, Taright N, Michaud S, Teixeira L, Cahen-Doidy L, Bourstyn E, **Espie M**, Hennequin C: 10-Year follow-up of 621 patients treated using high-dose rate brachytherapy as ambulatory boost technique in conservative breast cancer treatment. Radiother Oncol 2016
15. Delaloge S, Bachelot T, Bidard FC, **Espie M**, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Lorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, Andre F, Rouzier R: [Breast cancer screening: On our way to the future]. Bull Cancer 2016; 103: 753-63
16. Awada A, Cortes J, Martin M, Aftimos P, Oliveira M, Lopez-Tarruella S, **Espie M**, Lardelli P, Extremera S, Fernandez-Garcia EM, Delaloge S: Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. Clin Breast Cancer 2016; 16: 364-371
17. Cochereau D, Da Costa S, Le Maignan C, Gauthier H, Cochereau J, **Espie M**, Giacchetti S, Teixeira L: [Intrathecal methotrexate in breast cancer meningeal carcinomatosis - Experience with a new administration schedule]. Bull Cancer 2016; 103: 444-54
18. Hamy AS, Porcher R, Eskenazi S, Cuvier C, Giacchetti S, Coussy F, Hocini H, Tournant B, Perret F, Bonfils S, Charveriat P, Lacorte JM, **Espie M**: Anti-Mullerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies. Reprod Biomed Online 2016; 32: 299-307
19. Groheux D, Mankoff D, **Espie M**, Hindie E: F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. Eur J Nucl Med Mol Imaging 2016
20. Groheux D, Biard L, Giacchetti S, Teixeira L, Hindie E, Cuvier C, Vercellino L, Merlet P, de Roquancourt A, de Cremoux P, Resche-Rigon M, **Espie M**: 18FDG-PET/CT for the early evaluation of response to neoadjuvant treatment in triple negative breast cancer: influence of the chemotherapy regimen. J Nucl Med 2015
21. Cortes J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, **Espie M**, Kim SB, Schneeweiss A, Sohn JH, Nabholz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H: Afatinib alone or

- afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol 2015; 16: 1700-10
22. Frank S, Dupont A, Teixeira L, Porcher R, De Roquancourt A, Giacchetti S, **Espie M**, Cuvier C: Ductal carcinoma in situ (DCIS) treated by mastectomy, or local excision with or without radiotherapy: A monocentric, retrospective study of 608 women. Breast 2015; 25: 51-6
23. Maxwell F, de Margerie Mellon C, Bricout M, Cauderlier E, Chapelier M, Albiter M, Bourrier P, **Espie M**, de Kerviler E, de Bazelaire C: Diagnostic strategy for the assessment of axillary lymph node status in breast cancer. Diagn Interv Imaging 2015; 96: 1089-101
24. Goldstein SR, **Espié M**, Druckmann R: Does purified Swedish pollen extract, a nonhormonal treatment for vasomotor symptoms, inhibit the CYP2D6 enzyme system? Menopause N Y N 2015; 22:1212-4
25. Pivot X, Suter T, Nabholz JM, Pierga JY, **Espie M**, Lortholary A, Khayat D, Pauporte I, Romieu G, Kramar A, Fumoleau P: Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Eur J Cancer Oxf Engl 1990 2015; 51:1660-6
26. Groheux D, Majdoub M, Tixier F, Le Rest CC, Martineau A, Merlet P, **Espie M**, de Roquancourt A, Hindie E, Hatt M, Visvikis D: Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging 2015; 42: 1682-91
27. Tournaire M, Devouche E, **Espié M**, Asselain B, Levadou A, Cabau A, Dunbavand A, Grosclaude P, Epelboin S: Cancer Risk in Women Exposed to Diethylstilbestrol in Utero. Therapie 2015; 70:433-41
28. Groheux D, Majdoub M, Sanna A, Cremoux P de, Hindié E, Giacchetti S, Martineau A, Roquancourt A de, Merlet P, Visvikis D, Resche-Rigon M, Hatt M, **Espié M**: Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype. Radiology 2015; 277:358-71
29. Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, **Espie M**, Merlet P, de Roquancourt A, Visvikis D, Hatt M, Resche-Rigon M, Hindié E: Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer. J Nucl Med 2015; 56: 824-31
30. Nikpayam M, Uzan C, Rivera S, Delaloge S, Cahen-Doidy L, Giacchetti S, **Espie M**, Groheux D: Impact of radical surgery on outcome in locally advanced breast cancer patients without metastasis at the time of diagnosis. Anticancer Res 2015; 35: 1729-34
31. Coussy F, Teixeira L, Giacchetti S, Cuvier C, Hocini H, **Espié M**: [New targeted therapies in breast cancer]. Gynecol Obstet Fertil 2014; 42:787-94
32. Groheux D, Giacchetti S, Delord M, Roquancourt A de, Merlet P, Hamy AS, **Espié M**, Hindié E: Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging 2015; 42:377-85
33. Pierga J-Y, Delva R, Pivot X, **Espié M**, Dalenc F, Serin D, Veyret C, Lortholary A, Gligorov J, Joly K, Hernandez J, Hardy-Bessard A-C: [Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France]. Bull Cancer (Paris) 2014; 101:780-8

34. Hamy A-S, Porcher R, Cuvier C, Giacchetti S, Schlageter M-H, Coussieu C, Gronier H, Feugeas J-P, Adoui N, Lacorte J-M, Poirot C, Habdous M, **Espié M**: Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone. *Reprod Biomed Online* 2014; 29:573–80
35. Groheux D, Hindie E, Marty M, **Espié M**, Rubello D, Vercellino L, Bousquet G, Ohnona J, Toubert M-E, Merlet P, Misset J-L: ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. *Eur J Radiol* 2014; 83:1925–3
36. **Espié M**: The management of breast cancer. *Diagn Interv Imaging* 2014; 95: 753-7
37. Groheux D, Hindie E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, **Espié M**: Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. *Eur J Cancer* 2014; 50: 1864-71
38. Kramar A, Bachelot T, Madrange N, Pierga JY, Kerbrat P, **Espié M**, Fumoleau P, Pauporte I, Khayat D, Romieu G, Pivot X: Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. *Ann Oncol* 2014; 25: 1563-70
39. Hamy AS, Abuellella H, Hocini H, Coussy F, Gorins A, Serfaty D, Tournant B, Perret F, Bonfils S, Giacchetti S, Cuvier C, **Espié M**: Contraception after breast cancer: a retrospective review of the practice among French gynecologists in the 2000's. *Eur J Gynaecol Oncol* 2014; 35: 149-53
40. **Espié M**, Frank S: [The post-cancer period, a conceptual and epidemiological approach]. *Soins* 2014; 26-9
41. Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de The H, **Espié M**: Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. *Br J Cancer* 2014; 110: 1413-9
42. Nouri-Neuville M, de Rocquancourt A, Cohen-Zarade S, Chapellier-Canaud M, Albiter M, Hamy AS, Giachetti S, Cuvier C, **Espié M**, de Kerviler E, de Bazelaire C: Correlation between MRI and biopsies under second look ultrasound. *Diagn Interv Imaging* 2014; 95: 197-211
43. Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, **Espié M**, de The H: p53 in breast cancer subtypes and new insights into response to chemotherapy. *Breast* 2013; 22 Suppl 2: S27-9
44. **Espié M**, Wassermann J, de Kermadec E, Lalloum M, Coussy F: [Vitamin D and cancers]. *Presse Med* 2013; 42: 1405-11
45. Groheux D, Giacchetti S, Hatt M, Marty M, Vercellino L, de Roquancourt A, Cuvier C, Coussy F, **Espié M**, Hindie E: HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. *Br J Cancer* 2013; 109: 1157-64
46. **Espié M**, Lalloum M, Coussy F: [Epidemiology and risk factors of breast cancer]. *Soins* 2013; 22-4
47. Crown J, Kennedy MJ, Tresca P, Marty M, **Espié M**, Burris HA, Desilvio M, Lau MR, Kothari D, Koch KM, Dieras V: Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. *Ann Oncol* 2013; 24: 2005-11
48. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, **Espié M**, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S,

- Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporte I, Kramar A: 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013; 14: 741-8
49. Chan A, Conte PF, Petruzelka L, Tubiana-Mathieu N, Ganju V, Llombart A, **Espie M**, Majois F, Gil MG, Vaissiere N, Villanova G: Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. Anticancer Res 2013; 33: 2657-64
50. Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, Habuellelah H, Leman-Detours S, de Roquancourt A, Cahen-Doidy L, Bourstyn E, de Cremoux P, de Bazelaire C, Albiter M, Giacchetti S, Cuvier C, Janin A, **Espie M**, de The H, Bertheau P: Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res 2013; 15: R37
51. Richard R, Thomassin I, Chapellier M, Scemama A, de Cremoux P, Varna M, Giacchetti S, **Espie M**, de Kerviler E, de Bazelaire C: Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol 2013; 23: 2420-31
52. Groheux D, Hatt M, Hindie E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, **Espie M**: Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Cancer 2013; 119: 1960-8
53. Hatt M, Groheux D, Martineau A, **Espie M**, Hindie E, Giacchetti S, de Roquancourt A, Visvikis D, Cheze-Le Rest C: Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 2013; 54: 341-9
54. Groheux D, **Espie M**, Giacchetti S, Hindie E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology 2012;266(2):388-405.
55. Groheux D, Giacchetti S, Delord M, Hindie E, Vercellino L, Cuvier C, Toubert ME, Merlet P, Hennequin C, **Espie M**. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med 2013;54(1):5-11.
56. Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, **Espie M**, et al. Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer 2013;132(5):1227-31.
57. Valet F, Cremoux P de, Spyros F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, **Giacchetti S**, Brain E, Tembo O, Marty M, Asselain B: Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial. Breast Edinb Scotl 2013; 22:1052-9
58. Bidard F-C, Belin L, Delaloge S, Lerebours F, Ngo C, Reyal F, Alran S, **Giacchetti S**, Marty M, Lebofsky R, Pierga J-Y: Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study. Int J Breast Cancer 2013; 2013:130470